WHO Sounds Alert Over Severe Lack of Weight-Loss Injections
Fewer than 10% of individuals eligible to benefit from obesity jabs like Wegovy have access to them, warns the WHO as it releases its first guidance on the medications.
With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for increased and just availability to this class of drugs.
Based on forecasts, over two billion could be living with obesity by 2030 without intervention.
"Our latest guidelines recognises that obesity is a chronic disease that can be managed with comprehensive and continuous care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are major barriers to universal availability to the treatments that can help people shift significant weight, explains the organization.
Weight-Loss Drug Supply Crisis
Even in the current most optimistic scenario, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – less than 10% of eligible patients, as stated by the WHO.
The advice encourages nations and manufacturers to widen availability, by strategies including licensing agreements.
Exclusive production rights on the active ingredient – the main component of Novo Nordisk's Wegovy – is set to lapse in several nations in 2026.
How Obesity Jabs Function
These medications mimick a natural hormone to slow digestion, suppress the appetite and enhance the sense of being full so individuals eat less.
People typically see weight reduction within a few weeks of starting on the once-weekly jabs.
Studies suggests people may see weight return a year later of stopping the drug, when their usual food cravings come back.
To be carrying excess weight elevates your likelihood for experiencing diseases, including diabetes, heart disease, brain attack, and certain malignancies.
Obesity impacts people in all nations and was associated with over three and a half million fatalities worldwide in 2024, as per the health agency.
